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Abstract 
The increase of bacteria resistance to the conventional antibiotics has led scientists to 
focus their research on discovering new antimicrobial agents in order to eradicate this 
pressing global health issue. Antimicrobial peptides and their mimics are the leading 
answers to this problem. This report will investigate the relationship of one antimicrobial 
mimic; a peptoid and its mode of action with respect to bacteria, in this case E. coli. By 
analysing the effect of a known antibiotic, a studied antimicrobial peptide and a tested 
unknown analogous peptoid, the killing kinetics were assessed, by comparing Live/Dead 
Quantification assay and CFU counts. The findings show evidence that there might be a 
difference of the mode of action between these antimicrobial agents depending on the 
quantity used. 
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1. Introduction 
 
The Golden Age of antibiotics had great successes which led experts to believe viral and 
bacterial diseases would have been eliminated by the turn of the millennium. Because of 
these advances in antibiotics, most bacterial infections within developed countries have 
been uncomplicated to treat. 
In general this has not changed much, however the treatment of certain bacterial 
infections has gradually evolved to become more complicated in recent years because of 
increased antibiotic resistances. This is made obvious by the fact that more than one-third 
of the world population is likely infected by bacterial pathogens and two million fatalities 
occur per year from bacterial infections (http:// www.niaid.nih.gov/factsheets/tb.htm. 
Accessed May 17, 2014.). Infectious diseases are the third leading cause of death in 
developed countries, in spite of the availability of antibiotics (Nathan, 2004). 
Furthermore, the emergence of resistant bacteria such as methicillin-resistant 
Staphylococcus aureus (MRSA) was in 2005 estimated to have caused 94.000 infections 
leading to 19.000 deaths (Klevens et al. 2007). 
The rapidly evolving resistance development by Staphyloccus aureus has the potential to 
re-create a pre-antibiotic world with mortality rates of 80% for those patients 
systemically infected (Smith , Vickers,  1960). M. tuberculosis and S. aureus are two 
examples of bacterial pathogens that will exist and evolve dramatically as long as their 
host is viable. 
For whatever reason, the post Golden Age discovery of novel antibiotics was 
unsuccessful. To fill the void, researchers adopted the strategy of incrementally 
improving the existing classes of antibiotics, to be active against resistant bacterial 
pathogens. It is now accepted that resistance is inevitable, and that resistance 
management will be part of the process for all new antibiotics. 
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The aforementioned facts are by themselves worrying, but if you add the fact that there 
has only been introduced a very limited number of truly new antibacterial agents to the 
market in recent history, Figure 1, and a rapid declining interest from medical companies 
into development of new antibiotics, you have a development that calls for concern 
(Nussbaum et al., 2006; Fischbach, Walsh, 2009). 
 
Figure 1 Graph that shows total number of new antimicrobial agent since 1983 
 
The emergence in all regions of the world of strains of pathogenic bacteria and fungi with 
resistance to commonly used antibiotics constitutes a potentially serious threat to public 
health and leads to increased need for more sophisticated and potent drugs to fight against 
human pathogens. This contributes to massive research in the development of 
antimicrobial agents design and modification as human therapeutics. The project should 
give an overview of possible alternatives to antibiotics. 
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Figure 2 Left: CFU count for GN-2 peptide. Right: Live dead quantification based on the ratio of red fluorescence 
(dead bacteria) and green fluorescence (live bacteria). Percent of live bacteria after treatment with 1x, 2x and 4xMIC 
concentrations of peptides GN-2. 100% are set as the value from untreated samples at time 0 (Godballe, 2013). 
 
Peptides have shown to be effective against bacteria, even the ones resistant to certain 
types of antibiotics. However, they prove to be less effective in vivo because they can be 
degraded by proteases. On the other hand, peptoids are not degraded by proteases, and 
also demonstrate better membrane permeability. The present project is trying to answer 
what is the state of bacterial membranes, when treated with peptoids, and the mode of 
action of peptoids. 
 
 
2. Background 
 
The following section will seek to introduce the components of bacteria that are 
important for interaction with antimicrobial agents and give a brief introduction to a 
bacterial mediated pathological condition that AMPs have the potential to alleviate. As 
antibiotics and AMPs are thought to target some of the same bacterial components and to 
serve as foundation for comparison of the inhibitory actions with peptides, a brief outline 
of the mechanism of action for both the antibiotics and peptidomimetics will be 
presented. Finally, an introduction to the structure and characteristics of antimicrobial 
peptides and peptoids will be presented. 
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2.1  Bacteria Membranes 
 
There are two different types of bacteria: Gram-positive and Gram-negative. The 
differences lie in the structure of their membranes. Gram-negative bacteria, such as E. 
coli, have an outer phospholipid membrane, peptidoglycan layer, periplasmic space, and 
an inner phospholipid membrane. In comparison, Gram-positive bacteria do not have an 
outer phospholipid membrane; however, its distinguishing feature is the thickness of its 
peptidoglycan layer. Figure 3 shows the basic structure of the two types of bacteria. 
 
 
Figure 3:  Structures of Gram-negative and Gram-positive bacteria (Todar, 2009).  
Even with structural differences both types of bacteria still contain a phospholipid 
bilayer, which is two layers of phospholipids placed tightly side-by-side. Phospholipids 
are amphipathic meaning they have a hydrophobic and hydrophilic domain (see Figure 
3). The polar, hydrophilic head contains a phosphate group, glycerol, and another varied 
molecule while the nonpolar, hydrophobic end contains two fatty acid tails. For this 
reason, it is necessary for antimicrobial compounds, such as peptides and peptoids, to be 
amphipathic so they can bypass the membrane. Moreover, in both types, the periplasmic 
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space contains necessary enzymes for function, and the inner phospholipid bilayer is the 
same (Sørensen et al. 2012). 
Both bacteria have a peptidoglycan layer whose main purpose is to resist osmotic 
pressure keeping the bacteria from bursting. The structure of the peptidoglycan layer is 
made up of sugars and amino acids. N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) are connected one after the other in rows where amino acids, 
connected to the sugar NAM, form cross-linked bridges. There are similarities; however, 
there are unique differences between the two as well. In Gram-positive bacteria the 
peptidoglycan layer is around 20-80 nm while Gram-negative bacteria’s layer is around 
7-8 nm; furthermore, Gram-positive bacteria contain teichoic and lipoteichoic acids, 
which help with the structural integrity and give off an increased negative charge.  The 
cross-link bridges are also different. In Gram-positive bacteria the crosslinks are made 
from an interpeptide bridge consisting of glycosidic molecules while Gram-negative form 
an interpeptide bond (Sørensen et al., 2012). Figure 4 shows the structure of E. coli 
peptidoglycan layer with the correct amino acids used. 
 
 
Figure 4. a): Phospholipid,  b): E. coli peptidoglycan structure (Todar, 2009). 
Gram-negative bacteria’s outer membrane contains lipopolysaccharides, which help with 
the structural integrity of the membrane, and is classified as an endotoxin because it 
causes inflammation and toxicity when it dissociates from the membrane. Furthermore, it 
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increases the negative charge of the membrane, encouraging the electrostatic interactions 
of the positive charged antimicrobial compounds. 
Antibiotic Modes of action      
As our current treatment of bacterial infections is highly dependent on antibiotics and 
some antimicrobial peptides are believed to target the same bacterial components, a brief 
introduction of the antibiotics used in this study will be presented in the following 
section.       
Drug discovery in general, centres on the dogma of targeting only the processes needed 
for disease prevention without any adverse effects. Hence, to meet this general criterion 
the development of antibiotics relies on targeting processes or structures that are unique 
for bacteria such as the bacterial cell wall biosynthesis. Another strategy is to target 
elements in bacteria, such as protein synthesis and DNA replication/repair machinery that 
are sufficiently different in structure from their human counterparts to allow selective 
inhibition     
Generally, the mode of action of antibiotics can be described as either being bactericidal 
(bacteria-killing) or bacteriostatic (bacteria-inhibiting). These modes of action are very 
broad and don’t give much information as to how antibiotics kill the bacteria. Therefore, 
the different kinds of antibiotics can be further classified into five different modes of 
action: 
1.     Inhibitors of cell wall synthesis 
2.     Inhibitors of nucleic acid synthesis 
3.     Inhibitors of membrane function 
4.     Anti-metabolites 
5.     Inhibitors of protein synthesis 
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Cell Wall Synthesis Inhibitors 
 
Figure 5: Effect of β-lactams on cell wall cross-linking, which weakens the integrity of the cell wall resulting in 
bacterial lysis (Kohanski et al., 2010). 
Inhibitors of cell wall synthesis affect the peptidoglycan layer of bacteria in some way. 
For penicillin, or other beta-lactam antibiotics, the penicillin permanently blocks the 
active site of an enzyme (transpeptidase) responsible for creating the cross-link bridges 
between amino acids in the cell wall (figure 3). This leads to the weakening of the cell 
wall, and eventually the weakened cell wall cannot handle the osmotic pressure and 
undergoes lysis (Godballe, 2013). For this reason, beta-lactams and all other cell wall 
synthesis inhibitors are bactericidal. 
Nucleic Acid Synthesis Inhibitors 
 
Figure 6: The effects of quinolone on DNA gyrase form double stranded breaks and eventually leas to cell death 
(Kohanski et al. 2010). 
Inhibitors of nucleic acid synthesis can either be DNA or RNA inhibitors. Quinolones are 
a class of antibiotics that affect DNA gyrase, a topoisomerase responsible for under-
winding or over-winding DNA. As seen in Figure 6, quinolones allow the gyrase to cut 
the strands and then prevents relegation resulting in double stranded breaks of DNA. At 
high concentrations quinolones express a bactericidal effect by causing the fragmentation 
of the DNA, and at low concentrations it is bacteriostatic by stopping DNA replication 
and growth (Drlica et al, 2008). The RNA inhibitor rifamycin affects DNA dependent 
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RNA polymerase by binding to the active site and stopping the accumulation of products; 
ultimately, they affect transcription. 
Membrane function Inhibitors 
Inhibitors of cell membrane function are all bactericidal. They usually cause death of the 
cell by opening pores or passageways to allow leakage of molecules and allow water 
uptake leading to lysis. This is the case for the polymyxin sub-class of lipopeptides; 
however, another sub-class, cyclic lipopeptides, inhibits function by binding to ions and 
causing depolarization of the membrane and leading to the inhibition of intracellular 
synthesis (Zavascki et al, 2007). 
Anti-metabolites 
 
Figure 7: Shows the folate pathway with two different antibiotics affecting two different enzymes in the pathway, 
which has the same outcome of not being able to produce tetrahydrofolic acid (Mayer, 2010). 
Anti-metabolites interfere with bacteria by inhibiting different pathways necessary for 
survival. Sulfonamides interfere with the folate pathways responsible for the synthesis of 
folic acid by competitive inhibition of the 1st enzyme, pteridine synthetase (Figure 7), 
stopping the formation of dihydropteroic acid. This stops the formation of folic acid 
(tetrahydrofolic acid). The lack of folic acid interferes with the synthesis of adenine and 
thymine, and this eventually leads to the cell unable to replicate (Mayer, 2010). This 
makes sulfonamides bacteriostatic antibiotics; however, some anti-metabolites can 
express bactericidal effects. 
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Protein Synthesis Inhibitors 
 
Figure 8: Showing the bactericidal mode of action of aminoglycosides (Kohanski et al., 2010). 
 
The last type of mode of action is inhibitors of protein synthesis. These antibiotics 
usually affect translation by binding to the ribosome RNA, differences between 
prokaryotic and eukaryotic rRNA allow for better specificity and thus less toxicity 
towards mammalian cells. Specifically, tetracycline is an antibiotic that reversibly binds 
to the A site of the 30s ribosome subunit (see Figure 9). This binding prevents the 
incoming tRNA from rotating properly and binding to the mRNA codon, thus preventing 
protein synthesis from  
occurring. Protein synthesis inhibitors can be either 
bactericidal or bacteriostatic depending on the 
antibiotic and sometimes the concentration of said 
antibiotic. Aminoglycosides are bactericidal 
antibiotics while tetracycline is bacteriostatic 
(Godballe, 2013). The reader can refer to Figure 11 
for a graphical representation of the bacteriostatic nature of tetracycline.  
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Figure 13: Bactericidal effect of aminoglycosides. Incorporation of misfolded proteins in the membrane disrupts 
membrane function leading to both increased uptake of aminoglycoside and production of hydroxyl radicals which 
contributes to the lethal effect against bacteria (Kohanski et al., 2010). 
Tetracycline [Fig. 14] is a bacteriostatic drug that originally was isolated from Streptomyces 
aureofaciens, binds the 30s bacterial ribosomal subunit and thereby prevents protein 
biosynthesis. More specifically, tetracycline prevents the 
rotation of the incoming aminoacyl-tRNA anticodon into 
the A-site, ther by preventing binding to the mRNA 
codon (Franklin & Snow, 2005). This results in 
premature release and no formation of peptide bonds. 
The binding of tetracycline is reversible, which also 
serves to explain the bacteriostatic nature of the drug 
(Bryskier, 2005). Although tetracycline is also able to bind 80s mammalian ribosome, selectivity 
towards bacteria is ensured by a higher affinity towards bacterial ribosomes and selective 
uptake and accumulation of the drug in susceptible bacteria (Franklin & Snow, 2005).  
  
Figure 14: Molecular structure of Tetracycline. 
Figure 9: structure of tetracycline 
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Figure 10 killing kinetics of tetracycline. (Norcia et al, 1999) 
 
Peptides  
Peptides are short polymers of amino acids linked together by peptide (amide) bonds. 
This bond is a special linkage in which the nitrogen atom of one amino acid binds to the 
carboxyl carbon atom of another. Such a linkage is formed by removal of the elements of 
water (dehydration) from α-carboxyl group of one amino acid and the α-amino group of 
another. Peptide bond formation is an example of a condensation reaction, a common 
class of reactions in living cells.   
Peptides are of a great interest in medicine and biotechnology, since they have showed to 
regulate most processes, acting at some sites as endocrine or paracrine signals and at 
others as neurotransmitters or growth factors. (www.peptideguide.com, accessed 16 May 
2014).  
They are also used for diagnostic purposes, for instance C-peptide (connecting peptide) is 
used to monitor insulin production and to help determine the cause of low blood sugar - 
hypoglycemia (www.peptideguide.com, accessed 16 May 2014). 
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 They also play a very important role in molecular biology. Peptides permit the creation 
of peptide antibodies in animals, which can be done without the need to purify the protein 
of interest. Antigenic peptides of sections of the protein of interest are synthesized, these 
are used to make antibodies when placed in a rabbit or mouse that will counteract the 
protein (Bulinski, 1986). 
They have recently been used in the study of protein structure and function. For example, 
synthetic peptides can be used as probes to see where protein-peptide interactions occur. 
 
Antimicrobial peptides 
A very important class of peptides is antimicrobial peptides (AMPs), also called host 
defense peptides. They have been isolated from a wide range of organisms and vary in 
their antimicrobial effect from direct to immune modulators.  These peptides exhibit 
broad-spectrum activity against (Figure 2) a wide range of microorganisms including 
Gram-positive and Gram-negative bacteria, protozoa, yeast, fungi and viruses. A few 
peptides have also been found to be cytotoxic to sperm and tumour cells (Reddy et al. 
2004). 
Antimicrobial peptides are very diverse and they are organized into three groups by their 
origins. These groups are eukaryotic AMPs, bacteriocins, and phage-encoded AMPs, and 
are found in all forms of life including humans. These antimicrobial peptides have 
different structures which, also effects their antimicrobial activity and effectiveness. 
Although, there are a number of structural similarities that apply for most AMPs, usually 
being relatively short, ranging from 12-50 amino acids, carrying a net positive charge of 
+2 to +9 and having a distinct proportion of hydrophobic residues ( Jennsen, et al 2006). 
The four main structures are alpha-helical and beta-sheeted (the most abundant) and loop 
structure, and extended structure, Figure 11; however, there are other secondary 
structures and even combinations such as, a-helical and b-sheeted structures (Jenssen et 
al. 2006). 
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Figure 11: Antimicrobial Peptide Structure. (A) -sheeted (B) –helical (C) extended structure (D) loop structure. 
(Powers, Hancock, 2003)  
 
Examples of α-helical peptides include human isolated LL-37 and Magainin isolated 
from frog; β-sheet peptides encompass the human α- and β-defensins, and an example of 
a peptide with an extended structure is bovine isolated Indolicidin, used in this study as a 
reference peptide, Figure 12 (Hancock, Sahl, 2006).  
      
 
 
Figure 12: Secondary structure of the α-helical LL-37, extended structure of Indolicidin and the β-sheet structure of α- 
Defensin serving as examples of AMPs from different structural classes. Adapted from (Hancock, Sahl, 2006). 
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Eukaryotic AMP’s are cationic, positively charged, which allows them to interact with 
the bacterial anionic, negatively charged, membrane. In addition, they are amphipathic; 
contain both hydrophilic and hydrophobic parts (Parisien et al. 2007). These properties 
allow AMPs to attach to the cell wall and create pores on the membrane for increased 
permeability and loss of cell content (Parisien et al. 2007). 
Most known classes of AMPs are defensins, cathelicidins, and histatins. Defensins are the 
most abundant family of AMPs, and are characterized by their six cysteine residue 
molecules, which form a structure with disulfide bridges between two cysteine 
molecules. Defensins help protect against pathogens and kill bacteria, and they also help 
with the innate immune system. For example, HBD-3, a -human β defensin, shows strong 
antibacterial activity, salt-insensitiveness, and low toxicity for the host HBD-3 showed to 
be active against both Gram-positive and Gram-negative bacteria (Batoni et al. 2006). 
Although not researched as much as defensins, cathelicidins seem to be strong 
alternatives for antibiotics with their variety of sizes, sequences, and structures. 
Cathelicidins all have a N-terminal cathelin domain and a C-terminal cationic 
antimicrobial domain that becomes active after separation. Just like defensins, 
cathelicidins have important roles within the innate immune system and diverse 
antimicrobial activities; however, one special thing about cathelicidins is that they can 
bind to endotoxins and stop their harmful effects (Parisien et al. 2007).  This could be 
extremely helpful for Gram-negative bacteria that carry lipopolysaccharides; an 
endotoxin that is released when the cell wall begins to breakdown. The only human 
cathelicidin found is called LL-37, and is most abundant in neutrophils and various 
epithelial cells (Durr et al. 2006). In addition to its antimicrobial activity, it also seems to 
be a promoter of healing damaged tissue and skin (Heilborn et al. 2003). 
Peptides mode of action 
The increasing resistance of bacteria to conventional antibiotics stimulated the isolation 
and characterization of many antimicrobial peptides for potential use as new target 
antibiotics. The finding of thousands of antimicrobial peptides with variable lengths and 
sequences, all of which are active at similar concentrations, suggest a general mechanism 
for killing bacteria. 
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Antimicrobial peptides and are shown to have two different modes of action when 
interacting with bacteria, non-receptor mediated mechanism and receptor mediated 
mechanism.  
Firstly, the antimicrobial peptide must select and attach to the bacteria. The interaction 
with its outer membrane is thought to rely on electrostatic attraction and amphipathic 
properties of the peptides. AMP’s are usually cationic and are attracted to the anionic 
membranes of bacteria. They attack bacteria membranes because Gram-positive have 
teichoic acids which help increase the negatively charged membrane; in addition, Gram-
negative bacteria have lipopolysaccharides which also increase the already negative 
charged membrane. In addition, AMP attraction to bacteria is also facilitated by the 
transmembrane potential of bacteria around -120mV and the substantial fraction of 
negatively charged lipids of the membrane (Fjell et al.012). 
Most Eukaryotic cell membranes are zwitterionic and have in their composition neutral 
phospholipids, and as such they cannot mediate electrostatic attraction towards AMPs. 
For instance, cholesterol is thought to stabilize membranes and it is a very important 
component of many eukaryotic cells (Wessman, et al 2008), therefore countering 
potential membrane disrupting affect of AMPs against most eukaryotic cells. 
In summary, the reason why antimicrobial peptides attack bacteria cells and not host cells 
is because they are more attracted to the higher negative charged bacteria membranes 
rather than the neutral charge membrane of eukaryotic cells. With non-receptor mediated 
mechanism the goal is the bacterial membrane. 
The amphipathic form is what allows the AMP to function as an antibacterial activity 
because it is the hydrophobic and hydrophilic parts that allow it to permeate the 
membrane (Shai, 2002). The hydrophobic region interacts with the lipid part of the 
membrane, while the hydrophilic part interacts with either the head of the phospholipid or 
the lumen, empty space, of the pore. 
The receptor-mediated mechanism is usually restricted to AMP’s that come from bacteria 
like bacteriocins and lantibiotics. For example, Nisin Z connects itself to the lipid II cell 
wall precursor, which is responsible for cell wall biosynthesis. The antimicrobial peptides 
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that use the receptor-mediated mechanism are composed of two regions: a receptor-
binding domain, and a pore-forming domain. When the receptor-binding domain 
connects to the receptor the pore-forming domain is cleaved off and proceeds to permeate 
the membrane (Shai, 2002). 
There are two different ways that AMP’s permeate through the membrane. Most AMP’s 
will form some sort of pore to travel through; however, some AMP’s will translocate, 
move from one place to another, through the phospholipid bilayer without disturbing the 
membrane. AMP’s kill the bacteria usually by permeabilizing the membrane and causing 
lysis, rupture, that results in leakage of cell content or harmful materials getting into the 
cell; however, it has been proven that when a AMP translocates across the membrane it 
can cause failures to essential processes inside the cell such as, inhibition of DNA/RNA, 
protein, or cell wall synthesis, and few others (Jenssen et. al. 2006). 
There are a couple different types of models explaining how antimicrobial peptides work 
to permeabilize the membrane, but before going into the models explaining how the 
AMP’s interact with the phospholipid membrane is important. With Gram-negative 
bacteria, AMP’s arrive at the outer membrane where they take part in a process called 
self-promoted uptake, which is the act of displacing either or on lipopolysaccharides and 
creating instability of the membrane and allowing AMP’s to pass through. Figure 13 
illustrates the possible models of pore formation: (A) barrel-stave model (B) Carpet 
model (C) Toroidal model. Also Figure 13 is the process of translocation through the 
phospholipid membrane. 
The pore formations are based on a-helical structures and not b-sheeted structures 
because research and experiments are still needed to confirm it. Furthermore, uncertainty 
on the actual pore formations still lives because many factors come into play such as the 
concentration of the AMP and the possibility of multiple mechanisms of action (Jenssen 
et al. 2006). 
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Figure 13: Antimicrobial peptide pore-formation. (A left): Barrel-Stave model. (B): Carpet model. (C): Torodial model 
(Haney, Vogel, 2009).  
 
4. Peptidomimetics 
 
Peptidomimetics is the term used for groups of compounds that mimic the structure of a 
peptide and therefore the activity of a peptide. These compounds are obtained by 
structurally modifying peptides, using unnatural peptides or changing the conformation 
of the molecules (Simon et al, 1992). Peptidomimetics are made in order to counteract 
the problems that arise when using natural peptides, such as proteolysis, or to improve the 
potency and selectivity of a receptor (Vagner et al, 2008). Because of this study of their 
mode of action is essential to survey their potential in the drug discovery sector. 
Peptoids along with Beta-Peptides and many others are part of the peptidomimetic 
family. Beta-Peptides, are similar to peptoids in that the functional group has been 
moved, but instead of moving from the chiral carbon to the nitrogen like in peptoids, it 
has been moved to the beta carbon. Both have structural changes however peptoids use 
amines instead of amino acids and both are being experimented with in regards to 
antibiotic resistance. 
 
4.1 Peptoids  
Peptoids are a class of short polymers of N-substituted glycines that mimic peptides. 
Monomeric subunits are bonded together via a peptide bond, similarly to peptides which 
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has been previously discussed. Peptoids differ in the fact that the functional side chain is 
attached to the nitrogen atom instead of the chiral carbon of the monomers (Figure 14). 
The side chains used in the synthesis of peptoids subunits can be either amino acid 
functional groups or other synthetic groups (Goodson et al, 1999).  
 
Figure 14: the difference between peptides and peptoids (Simon et al., 1992) 
The nitrogen substitution necessary to produce them causes peptoids to have an achiral 
backbone. This provides more flexibility, however it means they lack stability when 
forming the helical structures found in peptides and are prevented from doing so (Wu et 
al, 2001). This is because they would require hydrogen bond donors, present in peptides, 
which form intramolecular bonds that stabilise these helices. It has been found that if 
monomers with chiral aromatic side chains are placed within a chain, they can form 
helices that mimic alpha helices found in peptides (Wu et al, 2001). 
Because peptoids chains are more flexible than their analogous peptides, they do not 
produce the same conformational structure (Zuckermann et al, 1994). However, as a 
whole group of chemicals, peptoids can mimic biologically active peptides, but with 
enhanced proteolytic stability (Fowler 2008). 
These similar, but significantly different, atomic structural differences between peptides 
and peptoids are what give study into peptoids importance.  
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5. Synthesis of peptoids 
Synthesis of peptoids is similar to that of peptides. Peptide synthesis is typically done on 
a solid phase but could be done in as liquid phase chemistry. In order to build the peptide 
one by one it must be easily separated from the solutions the make up one coupling cycle. 
This is achieved by linking peptide to a solid typically a resin made from beads of 
polystyrene. The beads act as easily separable objects in filtration. The resin comes in 
many varieties of different linkers depending on which organic chemistry is performed. 
Then by adding one amino acid at a time the peptide grows which in turn leads to the 
desired peptide. This is done by coupling the C-terminal group of the incoming amino 
acid to the N-terminal end of the growing chain. In nature, it is the other way around. 
Finally, the peptide is cleaved from the resin and purified. 
 
Before any of  these cycles are initiated, the resin is swelled and the linker is activated 
and the first submonomer is attached to the resin via the linker. Figure 15 shows the 
starting point where the repeated coupling cycles can be initiated. The protection group in 
this example is Fluorenylmethyloxycarbonyl (Fmoc) it could in theory be any of the 
commercially protection groups. The predominant properties of Fmoc is that of its 
bulkiness, the aromatic system, this prevents other lone pairs in attacking the N-terminal 
end of the peptoid.  
  
Figure 15: Protected resin bound peptoid and Removal of Fmoc (Chbrra, 2014) 
The first step is to activate the N-terminal by removing the Fmoc group. This is called 
deprotection as shown in Fejl! Henvisningskilde ikke fundet. Now another monomer 
can be coupled on to the peptoid chain, allowing it to become a polymer of waste 
combinations. 
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Figure 16: Coupling of a peptoid (Chbrra,2014). 
The steps could in theory be repeated infinitely, limitations lie in the side chains and their 
protections groups. As the peptoids chain grows the peptoids will be prone to folding and 
the global deprotection – the final step where all the protection groups are removed via en 
strong acid eg. Trifluoricaceticacid- would be compromised.    
Another approach to peptoids synthesis is submonomeric synthesis (Zuckermann et al, 
1992). The workflow consist of two steps. The first step is to acylate bromoaceticacid on 
to the n-terminal (Figure 17 a) using Disopropylcarbodiimide and then followed by 
reaction with a primary amine via nucleophilic displacement of the bromide (Figure 17 
b). 
 
 Figure 17: a) acylation of bromoacticacid b) nuclophillic displacement of bromine 
These submonomers together form the peptoids monomer, which again when steps a and 
b are repeated leads the final polymer. Like the first example at the end the peptoids is 
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cleaved from the resin using a mild acid making the peptoids as solute then the protection 
groups on the n-terminal of the side chains are removed. 
The process generally used in automated peptide/peptoids synthesizers are the 
submonomeric method. The experiments conducted in these test consist of 9-mer 
peptoids derived using the submonomeric method. 
6. Peptides vs. peptoids 
Peptoids and peptides are different in structure, it is because of this difference that they 
experience different results regarding permeability of cell membranes. On average, 
peptoids are 3- to 30-fold more effective at permeating the cell membrane than the 
analogous peptide. Their different structure affects four different parameters: 
lipophilicity, polar surface area, hydrogen bonding, and molecular size, volume, and 
rigidity (Tan et al. 2008).  
Hydrogen bonding is the primary parameter responsible for the efficiency of 
permeability. The peptoids seem to have the same amount of hydrogen bond acceptors as 
peptides; however, peptoids have lower amounts of hydrogen bond donors. The hydrogen 
bonds interfere with antimicrobial agents ability to passively diffuse across the membrane 
for two reasons. First, before reaching the membrane hydrogen bonds can form with the 
surrounding water. In order to move forward, energy to cleave these bonds is necessary, 
and having more bonds available will increase the amount of energy needed to break 
these interactions. Second, the hydrophilic part of the lipid membrane can bond with 
hydrogen donors hindering the agent even more (Tan et al. 2008) For these reasons, 
peptoids demonstrate better permeability because they have reduced amounts of 
hydrogen bond donors compared to their peptide counterparts. 
Another parameter that can affect permeability is lipophilicity, which is the ability of a 
chemical compound, peptoids and peptides, to dissolve in lipids or other non-polar 
solvents. The amino acids in the side chains of these compounds play a role in 
determining the lipophilicity of the compound because amino acids with excessive 
hydrophobicity will lead to poor solubility that leads to reduced permeability (Tan et al. 
2008). The lipophilicity in peptoids compared to their analogous peptides is lower due to 
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the structural difference. The nitrogen atoms in peptoids are tertiary making the 
compound more basic, which makes them more soluble and permeable. 
The third parameter is polar surface area (PSA), which is the sum of solvent-accessible 
surface areas. In other words, the surface sum of oxygen and nitrogen, including their 
attached hydrogens, can affect the permeability of compounds. Peptoids tend to have 
smaller PSA amounts (335.30 Å2) then peptides (358.80 Å2 ) because of a change from a 
secondary nitrogen to a tertiary nitrogen, which could make the peptoids more effective 
at permeating the membrane (Tan et al. 2008).However, PSA has only a minimal effect 
on the ability of the compounds to permeate through the membrane. 
The final parameter is molecular volume, size, and rigidity. For both peptides and 
peptoids the smaller the molecule the better the compounds is at permeating the 
membrane. The smaller the size and volume the less weight that compound carries, and 
this also contributes to the PSA. Molecular rigidity refers to the number of rotatable 
bonds; however, both peptoids and peptides tend to have the same amount of rotatable 
bonds. Peptides and peptoids aren’t much different in weight, and as such have only 
minimal roles in the permeability of peptides and peptoids.  
 
7. Experimental section  
Most of the experiments are carried out with the Escherichia coli strain ATCC 25922 as 
this is an established reference strain for antimicrobial testing (Wiegand et al, 2008) and 
has a biosafety level of 1, which minimizes the need for precautionary actions while 
conducting the experiments.  
 
Materials 
Bacterial strains: Escherichia coli ATCC 25922,  Antibiotics: Tetracycline Cat 
T7660,  96-well polypropylene microtitter plates (Cat. No. 3879, COSTAR), 96-well flat 
bottomed polystyrene Greiner plate (REF 655101),  Invitrogen, cat no 32430-027, 
LIVE/DEAD® BacLight TM Bacterial Viability Kit, L7012 (Invitrogen, 2004).  GN-
peptoids were synthesized using solid phase Fmoc chemistry, with amidation on the 
25 
 
carboxyl end, purified to a purity >95% using reversed phase HPLC and analyzed by 
mass spectrometry, before they were handed over to us.   
     
Optical Density  
The first step was to make an optical density vs. time standard curve to see the growth 
rate of the particular bacteria, in this case E. coli, over time. This is absolutely necessary 
for an experiment that tests to see the effectiveness of a antimicrobial compound by using 
the standard curve as a reference to see normal growth and that of bacteria treated with 
antimicrobial compounds. The method starts with a overnight grown culture of E. coli 
ATCC 25922, which was diluted 100x in 10 mL of MH (Mueller-Hinton) broth. The 
flask was placed in a shaking water bath at 37 ˚C to optimize growth. Using a pure MH 
broth 1 mL cuvette as a reference point, readings from a spectrophotometer were taken 
from 1 mL samples of the bacterial suspension at T0(time 0 minutes), T15, T30, T50, T70, 
and T85 until an O.D. of 0,1 was achieved.  
 
 
Live/Dead Ratio Standard Curve: 
After the OD standard curve a Live/Dead ratio vs. % live bacteria standard curve was 
made. Again the purpose of this standard curve is to the see the normal ratio of live/dead 
bacteria and compare it to the graphs acquired from testing with peptoid treated bacteria. 
The method is as follows. 1 mL of diluted culture with 0.1 OD is placed into each tube. 
The tubes are labeled L for live and D for dead. The two tubes are pelleted in a centrifuge 
at 12,000 rpm for 8 minutes, and once finished the supernatant is removed. For tube L the 
pellet is resuspended in 1 mL of NaCl 0.9%; however, for tube D the sample is 
resuspended with 50 µL of NaCl 0.9% and 950 µL of isopropyl alcohol 70%. Both tubes 
are then placed on ice for one hour while being shaken every 15 minutes. Tube D is 
pelleted again at the same settings, and resuspended in 1 mL of NaCl 0.9%. Different 
ratios of live bacteria (0%, 10%, 50%, 90%, and 100%) are created in tubes with a total 
of 400 µL to form 100 µL well triplicates for each percentage (see Table 1).  
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% live bacteria 0% 10% 50% 90% 100% 
L tube (µL) 0 40 200 360 400 
D tube (µL) 400 360 200 40 0 
Table 1: amount of live/dead bacteria in ml to create the 5 ratios 
After the contents have been transferred to a 96-well plate 100 µL of the staining solution 
is added to each of the 15 wells. The staining solution was created using LIVE/DEAD ® 
BacLight™ Bacterial viability kit L7012 with SYT09 green fluorescent nucleic acid stain 
known as compound A (A) and red-fluorescent propidium iodide stain known as 
compound B (B). In this experiment the solution was made by combining 2 mL of water, 
6 µL of A, and 6 µL of B then the solution was stored in the dark for 15 minutes before 
use. After the staining solution was added the well plate was stored in the dark for 15 
minutes before being placed in a multi-detection microplate reader Synergy HT. Green 
fluorescence was excited at 485 nm and the emission detected at 528 nm; the red 
fluorescence was excited at 530 nm and the emission detected at 645 nm.  
 
LIVE-DEAD Staining 
The LIVE-DEAD BacLight Bacterial Viability Kit, L7012 was applied to peptoid treated 
E. coli ATCC 25922 to investigate a visual indication of the membrane permeability 
capabilities of the peptoids. This kit contains the SYT09 green-fluorescent nucleic acid 
stain together with the red-fluorescent Propidium Iodine stain. They are both nucleic 
acids, but the differ in their spectral capabilities and their capacity to penetrate bacterial 
membranes. SYT09 is capable of staining both healthy bacterial cells and bacterial cells 
with damaged membranes, whereas Propridium Iodide is only able to penetrate bacterial 
cells with damaged membranes. This means that SY09 is used alone, it will stain both 
live and dead bacteria green independent of membrane integrity. Propidium Iodide will 
only penetrate damaged membrane and suppress the green fluorescence mediated by 
SYT09 of cells with damaged membranes. This allows for the use of these fluorescent 
dyes in conjunction to distinguish between cells with intact membranes which will appear 
green and dead cells with damaged membranes will appear red (Invitrogen,2004).  
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LIVE-DEAD Quantification assay 
The assay was essentially performed according to the instructions of the manufacturer. 
An overnight culture of E. coli ATCC 25922 was diluted 1:100 in fresh MH broth 
followed by incubation in water bath at 37 C , and let it grow until OD600 of 0,1. The 
peptoids were diluted to a final test concentration of 1x, 2xMIC for the NPE and 1x, 
4xMIC for the GN-2 and tetracycline (the positive control) respectively.  10 µL of each 
concentrations were added to a flat bottomed polystyrene Greiner plate before loading 
90µL of the bacteria suspension. 100µL  of bacteria was used as a negative control. Each 
well corresponded to one time point for each individual treatment. Duplicates were made. 
The plate was incubated at 37C and the samples were extracted to pcr tubes at the 
indicated time points of 0, 10, 20, 40, 80 and 120 minutes and immediately placed on ice. 
The samples were then centrifuged at 12000 RPM for 8 minutes , the supernatant 
removed and the pellet resuspended in 100µL  0.9% ice cold NaCl, to remove interfering 
media components. The contents of each pcr tube was then transferred to individual wells 
of flat bottomed polystyrene 96-well Greiner plate and mixed with 100µL staining 
solution. The staining solution was prepared initially by adding 3µL of both compound A 
and B, for each 1mL of distilled sterilized water. The plate was then incubated in the dark 
for 15 minutes before measuring fluorescence on a multi-detection microplate reader 
Synergy HT. Green fluorescence was excited at 485 nm and the emission detected at 528 
nm; the red fluorescence was excited at 530 nm and the emission detected at 645 nm.  
 
CFU Counts 
In order to obtain a greater understanding of whether the peptoids acted in bactericidal or 
bacteriostatic manner, and to establish a time-course of the inhibitory event, colony 
forming units (CFU) counts were monitored for 180 minutes, following peptide exposure 
at concentration corresponding to 1x, 2x and 4xMIC.  
A culture of E. coli ATCC25922 had been prepared and incubated overnight. It was then 
diluted in a 1:50 ratio of culture to fresh MH Broth  and regrown to an OD600 of 
approximately 0,4 before diluting to a turbidity of 0,1.  
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While the culture was growing, stock peptoid solutions were also prepared. This was 
achieved by diluting the original “GN-2 Nphe9 3mg/ml” solution into 100ul stocks of 1x, 
2x and 4xMIC concentrations (16, 32 and 64ug/ml respectively). 
90 ul of the bacterial culture was then pipetted into the wells of a 96 well plate, with 10ul 
of the desired peptoid solutions added to make the volume total 100ul. For the controls 
group, 100ul of Bacterial culture was used instead. The cover of the plate was then 
replaced and it was incubated at 37°C for 180 minutes. At T= 0, 20, 40, 80, 120 and 180 
a 10ul sample of each set was removed and placed in an eppendorf tube with 1ml ice cold 
0.9% NaCl solution to get a x102 dilution. Serial dilutions for each sample were carried 
out to produce dilutions at x103, x104, x105 and x106. 100ml of each of these dilutions 
were then spread on an agar plate with LB medium, these were then incubated at 30°C 
for 18-20 hours. Afterwards the colonies were counted and the results were recorded. 
 
8. Results 
To make a coherent presentation of the results the purpose and concept of each 
experiment will be established prior to highlighting the major findings of each 
experiment and whenever appropriate, compared to the literature. A detailed 
interpretation of the results and their significance is given in the Discussion section.  
Standard Curve: 
In order to make sense of our data and characterize membrane permeability controls were 
put through a live/dead quantification procedure. Ratios of the live (green) and dead (red) 
were extrapolated and produced a graph with a linear regression line (Figure 18). 
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Figure 18:  graph that shows the live/dead ratio that was gathered from the corresponding ratios of % live bacteria. 
The equation of the slope provides us with the necessary information to carry out further 
tests, and to have accurate data of the effectiveness of the peptoids. Below is an equation 
(Equation 1) with the reciprocal of the standard curve slope that when coupled with the 
ratio of live/dead cells produces the percentage of live cells. 
 
% 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 =  
𝐺𝑟𝑒𝑒𝑛 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
𝑅𝑒𝑑 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒
 𝑥 
1
0.1177
 
 
Equation 1:  Getting percentage of live cells by multiplying the ratio of live/dead readings with the reciprocal of the 
standard curve slope 
 
MIC Testing: 
Antimicrobial Agent MIC HA50 HA10 Selectivity Ratio 
GN-2 peptoid 32 µg/ml 
>128 
µg/ml 
>128 
µg/ml 
>4 
GN-2 Nphe9 16 µg/ml 
>128 
µg/ml 
>128 
µg/ml 
>8 
Npe13579 Nae2Nlys468 64 µg/ml 
>128 µg/ml 
>32 
µg/ml 
>0.5 
Tetracycline 1 µg/ml 
NT NT 
 
y = 0,1177x - 0,2671
R² = 0,97
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Table 2: Information on the antimicrobial agents used. Contains the MIC, Hemolysis activity (HA), and selectivity ratio 
(B. Mojsoska, unpublished data) NT-Not Tested.  
Minimum inhibitory concentration test were held before this experiment. The table above 
(Table 2) shows the values of the MIC, the hemolytic assay, and its selectivity ratio. The 
selectivity ratio was calculated using the equation below (Equation 2). HC10 stands for 
the hemolytic concentration where 10% hemolysis is observed. High selectivity ratios are 
a good sign that the peptoid is potentially potent and safe to use therapeutically. 
𝑆𝑒𝑙𝑒𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑅𝑎𝑡𝑖𝑜 (𝑆𝑅)   =   
𝐻𝐶10
𝑀𝐼𝐶
 
Equation 2: equation used to find the selectivity ratio of an antimicrobial agent. 
 
Bacterial Viability 
This experiment was for the purpose of examining whether the peptoid had a bactericidal 
or a bacteriostatic effect on E.coli. The bacteria were exposed to three different 
concentrations of the GN2-Nphe9 peptoid, MIC x1, MIC x2, and MIC x4 that are 
equivalent to concentrations of 16 µg/ml, 32 µg/ml, and 64 µg/ml respectively. The 
exposure was observed over 180 minutes and readings were gathered at T0, 20, 40, 80, 120, 180 
minutes. Below is Figure 19: A graph that shows the relationship between the Log of 
the colony forming units vs. time. that shows the plotted data of the CFU counts over 
time for the GN2-Nphe9 peptoid. Though the graph shows some inconsistences, a 
bactericidal effect is observed at drops in CFU at T20 for MIC x1 and x2, while a drastic 
drop was observed at T40 for MIC x4. The clear difference between x1, x2 and x4 
concentrations proves it is concentration dependent. 
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Figure 19: A graph that shows the relationship between the Log of the colony forming units vs. time. 
 
Quantification of Membrane Permeability   
Using two different fluorescent dyes the experiment is able to quantify membrane 
permeabilization by labelling live and dead bacteria. The assay was done with a black 96-
well plate with bacteria starting at OD600 0.1 and a specific concentration of a peptoid. 
Tests were done on three different peptoids with concentrations that can be seen in the 
legends of the graphs. 
GN2 
The graphs below (Figure 20 a and b) all represent the GN2 peptoid. There are some 
inconsistencies, but one thing that is common with all of them is that the bacteria 
experience extremely quick permeabilization when introduced to the peptoid showing a 
quick decline in % live cells 10 minutes in. MIC x4 shows that nearly all the bacteria 
died, and 2 out of 3 graphs show an increase at 20 minutes possible inferring the growth 
of a surviving population or slight recovery from the initial permeabilization. 
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Figure 20: Both A) and B) are  % live bacteria vs, time graphs of the GN2 peptoid.  
 
GN-2 Nphe9 
Below is a graph (Figure 21) representing the GN-2Nphe9 peptoid. This peptoid shows 
rapid permeability of the membrane as the others did; in addition, at 20 minutes the MIC 
x1 and x4 showed a recovery of cells or a growth of a surviving population. MIC x1 
shows as time increases a the slight growth, while the other two concentrations show 
similar patterns of permeability and decrease in % of live bacteria.  
Below, Figure 22 shows tetracycline compared to the GN-2Nphe9 peptoid. This gives an 
indication towards establishing the mode of action as not being intracellular but acting on 
the bacteria membrane. 
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Figure 21: A % live bacteria vs. time graph of the GN2-Nphe9 peptoid. 
 
Figure 22 Tetracycline compared to GN2-Nphe9. 
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9. Discussion and Conclusion 
The aim of the study was to gain general understanding of antimicrobial peptides with 
focus on examining the effectiveness of peptidomimetics such as peptoids as possible 
alternatives to antibiotics against E.coli. , The focus was mainly on comparing the 
efficiency of the GN-2 peptoid and the GN-2 peptide, which has been previously studied 
(Godballe, 2013). In addition, the effectiveness of the novel peptoid GN2-Nphe9 was 
compared to the GN-2 peptoid to clarify the mode of action of the peptoids by referring 
to a known antibiotic, in this case tetracycline. 
Similarities between the GN2 peptide and its analogous peptoid, include, their fast 
permeability of the membrane, as well as noticeable decrease in % live bacteria (see 
Figure 20). However, the peptoid at both concentrations show better permeability of the 
membrane than the peptide, as expected and this observation is supported by the finding 
that peptoids are in fact more permeabale than peptides due to structural differences (Tan, 
2008). In addition, the % live bacteria concentration of the peptoid at MICx1 decreases, 
while the peptide increases after its initial permeabilization.  
The GN2-Nphe9 is the only peptoid with data from both the bacterial viability and 
live/dead quantification tests. As can be seen from the graph (Figure 21) the MICx2 
seems to stunt the growth of the bacteria, as there is hardly any net increase. This would 
be consistent with a bacteriostatic antimicrobial compound (Figure 10).  
At MIC x4 for CFU count, one can see a drastic drop in cell number from around 3 
million to 183,000. At this concentration a clear bactericidal effect of the peptoid can be 
seen. The live/dead quantification test at MIC x4 also shows a similar drastic drop 
(Figure 19). This shows that the bacteria’s membranes are clearly permeabilized, and 
there is a huge decrease in the number of living cells. The GN2-Nphe9 peptoid seems to 
be a concentration dependent bactericidal antimicrobial agent. The data could suggest 
that the mode of action could be to disrupt the membrane where the inhibitory effect only 
happens when a critical concentration is reached. 
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Comparing GN2-Nphe9 (Figure 19) to the GN2 peptide ( Figure 2), one should expect 
the CFU count at MICx1 to have a steady level and then increase at the very end. The 
explanation for this is because at MICx1 the peptoid can permeabilize the membrane; 
however, instead of causing lysis of the cell it merely halts some metabolic process that 
stuns the bacteria’s growth, and as time continues it reestablishes growth. However this 
does not happen. A reason for this graphing error could be the result of a pipetting or 
plating error.  
At MIC x2  a small drop and then a recovery is observed with a fairly constant level of 
CFU for the rest of the time. The drops in both CFU and % live bacteria from the two 
different tests suggest that, not only was the peptoid able to permeabilize the membrane, 
like at MIC x1, but it also induced lysis in some cells explaining the drop in CFU. 
However, the concentration was not high enough to kill all the cells, so the bacteria were 
able to recover, though the environmental stresses kept it at a constant level. An initial 
decrease in cell number, and then a slow increase to signify recovery was expected.  
 Tetracycline is an antibiotic that has a known mode of action; a bacteriostatic protein 
synthesis inhibitor. As seen in the graphs, GN2-Nphe9 at MICx2 has a similar activity to 
Tetracycline at MICx8 (Figure 10 and Figure 22), however GN2-Nphe9 at MICx4, the 
CFU count is much lower showing, that it has a greater effect on the bacteria, that leans 
more towards a bactericidal activity 
The quantification of membrane permeabilization test for the GN2- Nphe9 bears a 
resemblance to the GN2 peptoid, and they both likely share the same mode of action. 
Some differences between the two include the MIC concentrations and the selectivity 
ratios. Judging from this, the GN2-Nphe9 should be a better choice for future therapeutic 
use. Furthermore, comparing this peptoid to the GN2 peptide one can see better results at 
higher MIC concentrations, and the peptoid also has the added benefit of not being able 
to be degraded by proteases.  
It was not possible to conclude if the GN2 peptoid was more effective than the analogous 
peptide; although, the peptoid did show better permeability of the membrane. The lack of 
duplicates and accurate data did not allow a solid answer as to which was better. With 
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regards to GN2- Nphe9, the data showed that it was a potent peptoid that permeabilized 
the membrane quickly and caused lysis and death of the bacteria. It is a concentration 
dependent bactericidal peptoid. The Npe1,3,5,7,9Nae2lys4,6,8 had inconclusive data and no 
conclusion was able to be drawn from it. Overall, the results were unable to clearly define 
the most effective peptoid or peptide; however, the data still showed the ability to kill 
bacteria well and possible modes of action. The peptoids are not only potent, but are safe 
regarding their possible future therapeutic use. Mistakes such as pipetting, or simply 
taking too long to perform the tests could be the reasons for anomalies in the data. Time 
constraints did not allow for more data to be gathered on the subject. For future testing, 
duplicates of data are necessary for legitimate results; in addition, tests like flow 
cytometry could be used for more reliable information. 
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11. Appendix 
 
1. Master data. 
 
1.1. Chemical structures  of the investigated peptoids 
 
1.2. GN-2 Peptoid 
 
 
Figure 23 structure of the GN-2 peptoid 
 
1.3. GN-2 NPhe9 Peptoid 
 
 
Figure 24 structure of the GN-2 NPhe9 peptoid 
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1.4. GN-2 Npe1,3,5,7,9 Nae2Nlys4,6,8 Peptoid 
 
 
Figure 25 structure of the GN-2 Npe1,3,5,7,9 Nae2Nlys4,6,8 Peptoid 
 
2. Reference graphs. 
 
2.1. Npe1,3,5,7,9 Nae2Nlys4,6,8. 
The graphs below (Figure 19A,B) all represent the Npe1,3,5,7,9 Nae2Nlys4,6,8 peptoid. 
Similar to the GN2 peptoid, this peptoid shows a rapid permeability of the membrane, 
and for figure 19A an increase is seen at 20 minutes indicating either the recovery of 
some bacteria or growth of a surviving population. The two different concentrations show 
similar patterns with the MIC x2 being more effective, as one would expect. 
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Figure 26: A) and B) are % live bacteria vs. time graphs of the NPE1,3,5,7,9 Nae2lys4,6,8 peptoid. 
 
 
2.2. Master data for establishing the Standard curve. 
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Figure 27 shows the standard curve 
 
Figure 28 shows the precision of the three trials on the standard curve 
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3. Raw data. 
 
3.1.1. Master assay data. Lab Work 1st April. Quantification of membrane 
permeabilization. Measuring fluorescence on a multi-detection microplate 
reader Synergy HT.  
 
 Conc 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 
16 
µg/mL 
16 
µg/mL 16 µg/mL 16 µg/mL 
16 
µg/mL 16 µg/mL 
GN2 C 4 MIC 
64 
µg/mL 
64 
µg/mL 64 µg/mL 64 µg/mL 
64 
µg/mL 64 µg/mL 
GN 
Pelgs C 1 MIC 
64 
µg/mL 
64 
µg/mL 64 µg/mL 64 µg/mL 
64 
µg/mL 64 µg/mL 
GN 
Pelgs E 2 MIC 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
Tet F 1 MIC 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 
Tet G 4 MIC 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 
E.coli H control             
         
         
 
Green fluorescence 485nm / 528nm 
    
 
Live 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 6 5 6 16 30 47 
GN2 C 4 MIC 2 3 5 1 2 3 
GN  d 1 MIC 13 8 10 19 36 48 
GN 
Pelgs e 2 MIC 12 9 9 13 24 32 
Tet F 1 MIC 17 22 30 22 12 29 
Tet G 4 MIC 23 21 28 7 27 5 
E.coli H control 19 15 13 29 65 157 
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Red fluorescence 530nm / 645nm 
    
 
Dead 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 9 8 9 8 9 10 
GN2 C 4 MIC 8 8 9 8 9 8 
GN 
Pelgs d 1 MIC 8 9 8 8 8 10 
GN 
Pelgs e 2 MIC 7 8 7 8 7 8 
Tet F 1 MIC 7 7 6 7 7 8 
Tet G 4 MIC 9 6 6 7 7 5 
E.coli H control 7 6 7 6 7 7 
         
 
 
 
       
 
Ratios 1 2 3 4 5 6 7 
 
A time 0 10 20 40 80 120 
GN2 B 1 MIC 5,66 5,31 5,66 16,99 28,32 39,93 
GN2 C 4 MIC 2,12 3,19 4,72 1,06 1,89 3,19 
GN 
Pelgs d 1 MIC 13,81 7,55 10,62 20,18 38,23 40,78 
GN 
Pelgs e 2 MIC 14,56 9,56 10,92 13,81 29,13 33,98 
Tet F 1 MIC 20,63 26,70 42,48 26,70 14,56 30,80 
Tet G 4 MIC 21,71 29,74 39,65 8,50 32,77 8,50 
E.coli H control 23,06 21,24 15,78 41,06 78,89 190,56 
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3.1.2. Master assay data. Lab Work 2nd April. Quantification of membrane 
permeabilization. Measuring fluorescence on a multi-detection microplate 
reader Synergy HT.  
 
Conc 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 
16 
µg/mL 
16 
µg/mL 16 µg/mL 16 µg/mL 
16 
µg/mL 16 µg/mL 
GN2 C 4 MIC 
64 
µg/mL 
64 
µg/mL 64 µg/mL 64 µg/mL 
64 
µg/mL 64 µg/mL 
NPE d 1 MIC 
64 
µg/mL 
64 
µg/mL 64 µg/mL 64 µg/mL 
64 
µg/mL 64 µg/mL 
NPE e 2 MIC 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
Tet F 1 MIC 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL 
Tet G 4 MIC 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 4 µg/mL 
E.coli H control             
          
 
        
 
Green fluorescence 485nm / 528nm 
    
 
Live 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 41 56 46 42 91 60 
GN2 C 4 MIC 18 18 15 15 11 5 
NPE d 1 MIC 59 51 66 65 83 127 
NPE e 2 MIC 86 78 81 1 114 142 
Tet F 1 MIC 97 135 123 1 94 62 
Tet G 4 MIC 97 88 74 84 59 75 
E.coli H control 70 66 107 128 210 282 
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Red fluorescence 530nm / 645nm 
    
 
Dead 1 2 3 4 5 6 7 
 
A   t=0 min t=10 min t=20 min t=40 min  
t= 80 
min 
t= 120 
min 
GN2 B 1 MIC 9 8 10 9 10 10 
GN2 C 4 MIC 9 11 11 10 10 9 
NPE d 1 MIC 9 8 9 9 8 9 
NPE e 2 MIC 9 9 9 8 10 10 
Tet F 1 MIC 8 9 9 8 9 10 
Tet G 4 MIC 9 8 8 9 9 9 
E.coli H control 8 8 9 8 12 9 
         
         
 
Ratios 1 2 3 4 5 6 7 
 
A time 0 10 20 40 80 120 
GN2 B 1 MIC 38,70 59,47 39,08 39,65 77,32 50,98 
GN2 C 4 MIC 16,99 13,90 11,59 12,74 9,35 4,72 
NPE d 1 MIC 55,70 54,16 62,31 61,36 88,15 119,89 
NPE e 2 MIC 81,19 73,63 76,47 1,06 96,86 120,65 
Tet F 1 MIC 103,02 127,44 116,11 1,06 88,74 52,68 
Tet G 4 MIC 91,57 93,46 78,59 79,30 55,70 70,80 
E.coli H control 74,34 70,09 101,01 135,94 148,68 266,21 
 
3.1.3. Master assay data. Lab Work 15th April. Quantification of membrane 
permeabilization. Measuring fluorescence on a multi-detection microplate 
reader Synergy HT.  
Conc 1 2 3 4 5 6 7 
 
GN-2 t=0 min t=10 min t=20 min 
t=40 
min  
t= 80 
min 
t= 120 
min 
A 1 MIC 
32 
µg/mL 32 µg/mL 
32 
µg/mL 
32 
µg/mL 
32 
µg/mL 
32 
µg/mL 
B 1 MIC 
32 
µg/mL 32 µg/mL 
32 
µg/mL 
32 
µg/mL 
32 
µg/mL 
32 
µg/mL 
C 2 MIC 
64 
µg/mL 64 µg/mL 
64 
µg/mL 
64 
µg/mL 
64 
µg/mL 
64 
µg/mL 
D 2 MIC 
64 
µg/mL 64 µg/mL 
64 
µg/mL 
64 
µg/mL 
64 
µg/mL 
64 
µg/mL 
E 4 MIC 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
F 4 MIC 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
128 
µg/mL 
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G control 0 µg/mL 0 µg/mL 0 µg/mL 0 µg/mL 0 µg/mL 0 µg/mL 
        
        Green fluorescence 485nm / 528nm 
    Live 1 2 3 4 5 6 7 
  GN-2 t=0 min t=10 min t=20 min 
t=40 
min  
t= 80 
min 
t= 120 
min 
A 1 MIC 135 117 113 4 36 137 
B 1 MIC 94 83 81 28 73 58 
C 2 MIC 54 54 43 42 21 190 
D 2 MIC 59 33 45 33 7 11 
E 4 MIC 16 17 29 15 4 25 
F 4 MIC 24 30 23 2 15 5 
G control 71 112 111 34 46 94 
        
        Red fluorescence 530nm / 645nm 
    Dead 1 2 3 4 5 6 7 
 
GN-2 t=0 min t=10 min t=20 min 
t=40 
min  
t= 80 
min 
t= 120 
min 
A 1 MIC 11 12 11 10 10 12 
B 1 MIC 11 13 11 9 11 11 
C 2 MIC 12 13 13 10 9 9 
D 2 MIC 11 13 14 10 6 10 
E 4 MIC 15 14 16 10 9 12 
F 4 MIC 17 16 14 10 10 9 
G control 10 10 11 10 9 8 
        
        Ratios 1 2 3 4 5 6 7 
  GN-2 0 10 20 40 80 120 
A 1 MIC 88,4 68,0 74,9 14,3 44,1 72,0 
B 
Std. 
devi 29,0 24,0 22,6 17,0 26,2 55,9 
C 2 MIC 41,7 28,4 27,7 31,9 15,9 89,9 
D 
Std. 
devi 3,5 14,8 1,4 6,4 9,9 126,6 
E 4 MIC 10,6 13,3 14,7 7,2 8,5 12,1 
F 
Std. 
devi 5,7 9,2 4,2 9,2 7,8 14,1 
G control 60,3 95,2 85,7 28,9 43,4 99,8 
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3.1.4. Master assay data. Lab Work 15th April (second experiment). 
Quantification of membrane permeabilization. Measuring fluorescence on a 
multi-detection microplate reader Synergy HT.  
green T0 T10 T20 T40 T80 T120 
mic1 42 79 72 118 75 167 
mic1 51 84 119 76 113 108 
mic2 73 92 71 44 45 45 
mic2 87 68 68 32 36 37 
mic4 35 31 37 27 28 27 
mic4 45 37 35 38 36 18 
control 133 126 130 142 169 241 
       
       Red Column1 Column2 Column3 Column4 Column5 Column6 
mic1 10 10 11 11 10 11 
mic1 10 11 11 12 10 7 
mic2 11 11 13 13 9 10 
mic2 13 13 13 12 12 12 
mic4 15 15 14 13 12 12 
mic4 16 14 15 14 15 11 
control 11 8 10 7 9 8 
 
3.1. CFU Counts.  
3.1.1. Master data from CFU count experiment 23rd April. 
  T=0 T=20 T=40 T=80 T=120 T=180 
control 
x10^4 376 280 488 1096 1096 Uncountable 
control 
x10^5 93 60 92 143 217 171*4 
control 
x10^6 10 3 9 24 43 Uncountable 
              
MIC x1 x10^3 Uncountable Uncountable Uncountable Uncountable Uncountable Uncountable 
MIC x1 x10^4 163 496 724 1088 2600 Uncountable 
MIC x1 x10^5 24 75 178 202 477 392 
MIC x1 x10^6 16 12 24 33 55 56 
              
MIC x2 x10^3 Uncountable 1112 Uncountable Uncountable Uncountable Uncountable 
MIC x2 x10^4 376 216 896 295 564 280 
MIC x2 x10^5 60 37 124 33 55 92 
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MIC x2 x10^6 13 9 13 8 15 22 
              
MIC x4 x10^3 97 18 14 15 10 5 
MIC x4 x10^4 10 4 4 10 8 5 
MIC x4 x10^5 Uncountable 9 10 9 Uncountable 3 
  
3.1.2. Master data from CFU count experiment 7th May. 
  T=0 T=20 T=40 T=80 T=120 T=180 
control x10^4 264 62 372 Uncountable Uncountable Uncountable 
control x10^5 27 2 59 200 217 504 
control x10^6 2 0 7 27 43 75 
              
MIC x1 x10^4 53 11 294 Uncountable Uncountable Uncountable 
MIC x1 x10^5 3 1 2 192 208 156 
MIC x1 x10^6 2 0 3 14 32 29 
              
MIC x2 x10^4 284 8 13 660 780 476 
MIC x2 x10^5 14 0 1 63 68 72 
MIC x2 x10^6 3 0 0 Uncountable 6 10 
              
MIC x4 x10^3 0 0 1 3 0 0 
MIC x4 x10^4 0 0 0 0 0 0 
MIC x4 x10^5 4 0 0 0 0 0 
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4. Outliers. 
 
Determining the outliers in the experimental data collected in the CFU count experiment 
the use of simple statistics is applied.  The formula used for the standard deviation over 
the whole population at a given time point: 
√
∑(𝑥 − ?̅?)
𝑛
 , ?̅? = 𝑚𝑒𝑎𝑛  
The criteria of outliers are defines as, if the sample subtracted from the mean value has 
more than 50% deviation from the std. dev., then it is classified as an outlier. An example 
given in Table 3 and Table 4: 
Table 3 shows the original dataset for all the MIC 1 experiments. 
Minutes 0 20 40 80 120 180 
MIC x1 16300000 49600000 72400000 
10880000
0 
26000000
0   
MIC x1 24000000 75000000 
17800000
0 
20200000
0 
47700000
0 
39200000
0 
MIC x1 160000000 
12000000
0 
24000000
0 
33000000
0 
55000000
0 
56000000
0 
MIC x1 5300000 1100000 29400000       
MIC x1 3000000 1000000 2000000 
19200000
0 
20800000
0 
15600000
0 
MIC x1 20000000   30000000 
14000000
0 
32000000
0 
29000000
0 
middel 38100000 49340000 91966667 
19456000
0 
36300000
0 
34950000
0 
Std. 
dev. 
55028962,0
7 45420683 87127219 75812231 
12995999
4 
14756269
9 
 
|381000000 − 160000000| = 124900000 
1,5 ∙ 55028962,07 = 8253443,1 
124900000 > 8253443,1 ⟹ 𝑂𝑢𝑡𝑙𝑖𝑒𝑟 
Table 4 the same dataset as in table 1 evaluated for outliers. 
Minutes= 0 20 40 80 120 180 
MIC x1 NORMAL NORMAL NORMAL NORMAL NORMAL N/A 
MIC x1 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL 
MIC x1 OUTLIER OUTLIER OUTLIER OUTLIER NORMAL NORMAL 
MIC x1 NORMAL NORMAL NORMAL N/A N/A N/A 
MIC x1 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL 
MIC x1 NORMAL N/A NORMAL NORMAL NORMAL NORMAL 
 
